$500K top-up for biotech developing therapeutics for untreatable muscle disorders
News / 13 September 2024
Pioneering biotech company Myostellar, led by EMBL Australia leadership team members Professor Peter Currie and Associate Professor Mikaël Martino, has received a $500,000 top-up from CUREator to continue developing new therapies for debilitating muscular dystrophies.